within Pharmacolibrary.Drugs.ATC.A;

model A07EA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.09,
    Cl             = 13 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 9 / 1000000,
    adminCount     = 1,
    Vd             = 0.0022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0045000000000000005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Budesonide is a glucocorticoid steroid with potent anti-inflammatory properties. It is primarily used in the treatment of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and is approved for oral and inhaled use in numerous countries. It has a significant first-pass metabolism, limiting its systemic effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Gupta, SK, et al., &amp; Song, IH (2022). Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis. <i>Journal of pediatric gastroenterology and nutrition</i> 75(2) 186–191. DOI:<a href=&quot;https://doi.org/10.1097/MPG.0000000000003482&quot;>10.1097/MPG.0000000000003482</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35666852/&quot;>https://pubmed.ncbi.nlm.nih.gov/35666852</a></p></li><li><p>Tambucci, R, et al., &amp; De Angelis, P (2023). Oral Viscous Budesonide in Children With Eosinophilic Esophagitis After Repaired Esophageal Atresia: A Clinical Trial. <i>Journal of pediatric gastroenterology and nutrition</i> 77(2) 249–255. DOI:<a href=&quot;https://doi.org/10.1097/MPG.0000000000003830&quot;>10.1097/MPG.0000000000003830</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37195886/&quot;>https://pubmed.ncbi.nlm.nih.gov/37195886</a></p></li><li><p>Simeoli, R, et al., &amp; Goffredo, BM (2024). Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia. <i>Pharmaceutics</i> 16(7) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics16070872&quot;>10.3390/pharmaceutics16070872</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39065569/&quot;>https://pubmed.ncbi.nlm.nih.gov/39065569</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07EA06;
